| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Scholar Rock Holding Corp | Chief Medical Officer | Common Stock | 258,496 | $4,117,505 | $15.93 | 14 Feb 2022 | Direct |
| Keros Therapeutics, Inc. | Chief Medical Officer | Common Stock | 44,000 | $1,936,440 | $44.01 | 18 Feb 2025 | Direct |
| Tourmaline Bio, Inc. | Chief Medical Officer | Common Stock | 56,836 | $965,644 | $16.99 | 19 Oct 2023 | Direct |
| Keros Therapeutics, Inc. | Chief Medical Officer | Employee Stock Option (right to buy) | 110,000 | 08 Nov 2024 | Direct | ||
| Tourmaline Bio, Inc. | Chief Medical Officer | Employee Stock Option (Right to Buy) | 73,211 | 23 Oct 2023 | Direct | ||
| Scholar Rock Holding Corp | Chief Medical Officer | Stock Option (Right to Buy) | 37,500 | 14 Feb 2022 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| KROS | Keros Therapeutics, Inc. | 18 Feb 2025 | 1 | $0 | 4 | Chief Medical Officer | 19 Feb 2025, 16:15 |
| KROS | Keros Therapeutics, Inc. | 08 Nov 2024 | 1 | $0 | 4 | Chief Medical Officer | 12 Nov 2024, 16:15 |
| KROS | Keros Therapeutics, Inc. | 01 Nov 2024 | 0 | $0 | 3 | Chief Medical Officer | 08 Nov 2024, 16:18 |
| TALS | Tourmaline Bio, Inc. | 19 Oct 2023 | 3 | $0 | 4 | Chief Medical Officer | 23 Oct 2023, 20:20 |
| TALS | Tourmaline Bio, Inc. | 19 Oct 2023 | 0 | $0 | 3 | Chief Medical Officer | 23 Oct 2023, 18:28 |
| SRRK | Scholar Rock Holding Corp | 14 Feb 2022 | 2 | $0 | 4 | Chief Medical Officer | 15 Feb 2022, 16:15 |
| SRRK | Scholar Rock Holding Corp | 15 Jan 2022 | 1 | -$27,657 | 4 | Chief Medical Officer | 19 Jan 2022, 18:01 |